KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accounts Payables (2016 - 2025)

Regeneron Pharmaceuticals has reported Accounts Payables over the past 17 years, most recently at $939.0 million for Q4 2025.

  • Quarterly results put Accounts Payables at $939.0 million for Q4 2025, up 18.94% from a year ago — trailing twelve months through Dec 2025 was $939.0 million (up 18.94% YoY), and the annual figure for FY2025 was $939.0 million, up 18.94%.
  • Accounts Payables for Q4 2025 was $939.0 million at Regeneron Pharmaceuticals, up from $903.8 million in the prior quarter.
  • Over the last five years, Accounts Payables for REGN hit a ceiling of $939.0 million in Q4 2025 and a floor of $427.0 million in Q3 2021.
  • Median Accounts Payables over the past 5 years was $562.8 million (2021), compared with a mean of $611.1 million.
  • Biggest five-year swings in Accounts Payables: fell 13.37% in 2022 and later skyrocketed 81.74% in 2025.
  • Regeneron Pharmaceuticals' Accounts Payables stood at $564.0 million in 2021, then grew by 4.47% to $589.2 million in 2022, then grew by 2.95% to $606.6 million in 2023, then surged by 30.15% to $789.5 million in 2024, then grew by 18.94% to $939.0 million in 2025.
  • The last three reported values for Accounts Payables were $939.0 million (Q4 2025), $903.8 million (Q3 2025), and $723.9 million (Q2 2025) per Business Quant data.